The Technology of Sherbrooke, Quebec, Canada, based company, Imeka Inc. Used in Study on Promising Drug to Treat Alzheimer’s DiseaseSherbrooke, QC, Canada July 15 2020 – The Sherbrooke-based company Imeka (www.imeka.ca), with an office in Cambridge, Massachusetts, USA, is a brain imaging technology platform company that specializes in microstructure and white matter connectivity. Imeka has recently worked in collaboration with the biotech company INmune Bio Inc. in a clinical study, to demonstrate the efficiency of its drug XPro1595’s ability to reduce neurological inflammation in patients with Alzheimer’s disease.
Based in California, INmune Bio Inc. announced earlier this week the preliminary results of phase 1b clinical trial. With Imeka’s biomarker technology, the study has demonstrated that XPro1595 shows a reduction of 40.6% neurological inflammation in patients with Alzheimer’s disease.
In this study, Imeka’s noninvasive MRI based biomarker technology was used to analyze free water as a marker of neuroinflammation in patients.
“The results observed, although preliminary, are encouraging in regards of effectiveness of XPRO1595 to decrease neuroinflammation, which is the objective of our client INmune Bio Inc. to fight Alzheimer’s disease.” Explains Maxime Descoteaux, co-founder and scientific director at Imeka.
“Imeka’s technology has allowed us to examine neuroinflammation in a way that has not been available previously, said CJ Barnum, Director of Neuroscience for INmune Bio. “ To show, with very few patients, a robust reduction in neuroinflammation in an area of the brain important for Alzheimer’s disease is beyond anything I could have expected at such an early stage in our trial and I am excited to unleash the full potential of Imeka’s technologies in our studies.”
“INmune Bio Inc. partnered with Imeka for this important project and we are grateful for their trust in our company. Our work with them unfolds wonderfully and our collaboration will continue in subsequent phases of the project, for which we will follow the evolution of the clinical studies,” explains Jean-René Bélanger, Imeka’s CEO.
Imeka offers pharmaceutical companies an ability to combine diffusion MRI imaging and AI to map white matter integrity and understand neuroinflammation, demyelination and axonal loss. The Sherbrooke company also works in collaboration with pharmaceutical companies in the development of treatments for neurodegenerative diseases, such as, Multiple Sclerosis, Alzheimer’s and Parkinson’s disease.